|
In the spotlight
The American Diabetes Association (ADA) reports there are currently 20.8 million people with diabetes mellitus (DM) in the United States, or 7-8% of the population, and approximately 1.5 million new cases are diagnosed each year. Approximately 44% of people who are newly diagnosed as having chronic kidney disease are individuals with DM. Providence Medical Research Center (PMRC) is one of approximately 50-80 centers in North America who will be participating in a research study of an investigational drug for patients with Type 2 Diabetes Mellitus (T2DM). Management with current medications that treat the complications of T2DM, such as diabetic kidney disease, may not sufficiently reduce the rate and onset of damage to the kidneys. The consequence of this damage is improper filtering by the kidneys and excess protein in the urine or "proteinuria". Previous research has shown that treatments that reduce proteinuria, which is a common sign of T2DM related to declining kidney function, can slow progression of diabetic kidney disease. This study is designed to determine the effect of the investigational drug on proteinuria and also on kidney function. There are many factors known to lead to the decline in renal function for people who have T2DM. High blood pressure, high blood sugar levels, and potentially high cholesterol levels all play a role in the loss of kidney function. Recent research has found another contributor to a decline in renal function is an increase in Connective Tissue Growth Factor (CTGF), a protein the body normally produces. CTGF acts along with many other proteins to regulate the production of fibrous tissues in the body. It is thought that when CTGF is too high, growth of this fibrous or scar-like tissue occurs in the kidney. This results in loss of kidney function and proteinuria. Previous studies have found that current medications that treat hypertension and diabetes may help to protect the kidneys from damage, but they do not completely normalize CTGF levels. This study will also examine the effects of an investigational drug on CTGF levels. We at Providence Medical Research Center are proud to be a part of this important study. |
Learn more about us!
Providence Medical Research Center is the only physician-led, full-spectrum medical research center in the Inland Northwest. The program truly lives up to the "bench-to-bedside-to-community" paradigm. We conduct research at many levels.
Learn More:
You can help support the mission of Providence Medical Research Center. Your tax-deductible gift will help us advance medical innovations that help people around the world.
Click the image to donate online.
Providence Medical Research Center is located in The Fifth & Browne Medical Building (East Building).
Our mailing address is: Find maps and driving directions. Using the "Maps and Directions" link above, click on the mapquest icon to be sent to a pre-filled form with our address. Simply fill in your address for custom driving directions.
Our annual report provides a summary of research done at Providence Medical Research Center, along with publications, speaking engagements, and other activities and areas of service to our community.
|
Study Keyword Search
Recent Publications
Longitudinal Relationships among Coronary Artery Calcification, Serum Phosphorus, and Kidney Function
Longitudinal Relationships among Coronary Artery Calcification, Serum Phosphorus, and Kidney Function Clinical Journal of the American Society of Nephrology Published ahead of Print November 5, 2009 Katherine R. Tuttle and Robert A. Short Background and objectives: Coronary artery calcification (CAC) is common in advanced chronic kidney disease (CKD), yet its onset and time course are uncertain. The study objective was to assess longitudinal relationships among CAC, kidney function, and traditional and putative cardiovascular disease (CVD) risk factors. More Publications
A Multicenter, Randomized Trial of Treatment for Mild Gestational Diabetes (2009-12-03)
New England Journal of Medicaine Volume 361:1339-1348, October 1, 2009 Mark B. Landon, M.D., Catherine Y. Spong, M.D., Elizabeth Thom, Ph.D., Marshall W. Carpenter, M.D., Susan M. Ramin, M.D., Brian Casey, M.D., Ronald J. Wapner, M.D., Michael W. Varner, M.D., Dwight J. Rouse, M.D., John M. Thorp, Jr., M.D., Anthony Sciscione, D.O., Patrick Catalano, M.D., Margaret Harper, M.D., George Saade, M.D., Kristine Y. Lain, M.D., Yoram Sorokin, M.D., Alan M. Peaceman, M.D., Jorge E. Tolosa, M.D., M.S.C.E., Garland B. Anderson, M.D., ABSTRACT Background It is uncertain whether treatment of mild gestational diabetes mellitus improves pregnancy outcomes. Methods Women who were in the 24th to 31st week of gestation and who met the criteria for mild gestational diabetes mellitus (i.e., an abnormal result on an oral glucose-tolerance test but a fasting glucose level below 95 mg per deciliter [5.3 mmol per liter]) were randomly assigned to usual prenatal care (control group) or dietary intervention, self-monitoring of blood glucose, and insulin therapy, if necessary (treatment group). The primary outcome was a composite of stillbirth or perinatal death and neonatal complications, including hyperbilirubinemia, hypoglycemia, hyperinsulinemia, and birth trauma. View the article on line |
